Expression of SIRT1 in cancer - Staining overview

The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with high, medium, low or not detected (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.

The cancers can be ordered histologically or alphabetically.

For each cancer, the staining for each available antibody is reported as the fraction of samples with antibody staining level high, medium, low or not detected (as described by the color-coding scale in the box to the right). The length of the bar represents the number of patient samples analyzed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.

At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the literature conformity for the staining pattern revealed by that specific antibody.

Antibody HPA006295

Antibody CAB003855

Tissue

Antibody staining

Summary

Strong nuclear immunoreactivity, often accompanied with weak to moderate cytoplasmic staining, was observed in cervical and ovarian cancers and in embryonal carcinomas of testis. In squamous cell carcinomas, keratinized parts were strongly stained. Some endometrial cancers displayed additional membranous positivity. Most other tumors were weakly or moderately stained in cytoplasm or nuclei.

Most malignant cells were negative or displayed weak nuclear immunoreactivity. Strong staining was observed in testicular cancers and in rare cases of head & neck-, lung- and liver cancers.

Literature conformity

Partly consistent with extensive gene/protein characterization data

Level of antibody staining/expression

High
Medium
Low
Not detected

The Human Protein Atlas project is funded by the Knut & Alice Wallenberg foundation.